Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and devastating disease, which is characterized by invasiveness and dissemination to the lymphatic system and distant organs. In the absence of effective screening methods considerable efforts have thus been made to identify better systemic treatments than gemcitabine, the standard of care for advanced PDAC for well over a decade. However, until now only erlotinib, an epidermal growth-factor receptor tyrosine kinase inhibitor, has demonstrated a modest survival benefit in combination with gemcitabine in a phase III clinical trial. More recently, detailed global genomic analyses have provided a snapshot of the landscape of tumor genomes by showing that they contain four high frequency mutated genes and many low frequency mutated genes that correspond to 12 core signaling pathways. Strategies to target these frequently altered genes and their pathways, or low frequency mutated genes corresponding to the “personalized genome”, offer novel therapeutic strategies. In the near future, the complete sequencing of the coding genome, together with the dramatically reduced costs of whole genome sequencing, will provide new opportunities to treat PDAC.
Keywords: Whole genome sequencing, KRAS, TP53, CDKN2A/p16, SMAD4/DPC4, hedgehog pathway, personalized genome
Current Pharmaceutical Design
Title:Novel Therapeutic Approaches in Pancreatic Cancer Based on Genomic Alterations
Volume: 18 Issue: 17
Author(s): Shinichi Yachida
Affiliation:
Keywords: Whole genome sequencing, KRAS, TP53, CDKN2A/p16, SMAD4/DPC4, hedgehog pathway, personalized genome
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and devastating disease, which is characterized by invasiveness and dissemination to the lymphatic system and distant organs. In the absence of effective screening methods considerable efforts have thus been made to identify better systemic treatments than gemcitabine, the standard of care for advanced PDAC for well over a decade. However, until now only erlotinib, an epidermal growth-factor receptor tyrosine kinase inhibitor, has demonstrated a modest survival benefit in combination with gemcitabine in a phase III clinical trial. More recently, detailed global genomic analyses have provided a snapshot of the landscape of tumor genomes by showing that they contain four high frequency mutated genes and many low frequency mutated genes that correspond to 12 core signaling pathways. Strategies to target these frequently altered genes and their pathways, or low frequency mutated genes corresponding to the “personalized genome”, offer novel therapeutic strategies. In the near future, the complete sequencing of the coding genome, together with the dramatically reduced costs of whole genome sequencing, will provide new opportunities to treat PDAC.
Export Options
About this article
Cite this article as:
Yachida Shinichi, Novel Therapeutic Approaches in Pancreatic Cancer Based on Genomic Alterations, Current Pharmaceutical Design 2012; 18 (17) . https://dx.doi.org/10.2174/13816128112092452
DOI https://dx.doi.org/10.2174/13816128112092452 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diagnosis and Treatment of Paraneoplastic Neurological Syndromes
Current Clinical Pharmacology The Heat Shock Connection of Metabolic Stress and Dietary Restriction
Current Pharmaceutical Biotechnology Prognostic and Predictive Value of Epithelial to Mesenchymal Transitionassociated Markers in Oral Squamous Cell Carcinoma
Current Proteomics HPV Cervical Infection and Immunodysregulation: Synergistic Risks for Neoplasia-Review
Current Women`s Health Reviews Perspectives on Chemopreventive and Therapeutic Potential of Curcumin Analogs in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry RNA Interference-Mediated Validation of Survivin and Apollon/BRUCE as New Therapeutic Targets for Cancer Therapy
Current Topics in Medicinal Chemistry Molecular Interplay between Platelets and the Vascular Wall in Thrombosis and Hemostasis
Current Vascular Pharmacology YB-1 Protein and Multidrug Resistance of Tumor Cells
Current Signal Transduction Therapy The Beneficial Effects of Sulfur-containing Amino Acids on Cisplatininduced Cardiotoxicity and Neurotoxicity in Rodents
Current Medicinal Chemistry Cytotoxic and Allergenic Potential of Bioactive Proteins and Peptides
Current Pharmaceutical Design Inflammatory Bowel Disease and Celiac Disease: Overlaps in the Pathology and Genetics, and their Potential Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets Selected Players in the Inflammation Cascade and Drugs That Target These Inflammation Genes Against Metastasis
Anti-Cancer Agents in Medicinal Chemistry Pancreatic Cancer: Systemic Combination Therapies for a Heterogeneous Disease
Current Pharmaceutical Design Chronic Exposure to Low-Level Cadmium in Diabetes: Role of Oxidative Stress and Comparison with Polychlorinated Biphenyls
Current Drug Targets Birt-hogg-Dubé Syndrome Incidentally Identified in a Potential Liver Donor
Current Medical Imaging A Review of Diabetes Mellitus and Exposure to the Environmental Toxicant Cadmium with an Emphasis on Likely Mechanisms of Action
Current Diabetes Reviews Development, Characterization and in vivo Localization Study of Topical 5-Fluorouracil Gels: A Comparative Study with Conventional Formulation
Current Drug Delivery Is Tretinoin Still a Key Agent for Photoaging Management?
Mini-Reviews in Medicinal Chemistry Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors
Current Topics in Medicinal Chemistry